Jump to Main Contents
研究所ロゴ

Home > Division of Cancer RNA Research

Division of Cancer RNA Research

News

Nov. 21, 2024
Hirotaka Matsui delivered a talk onDDX41 scRNA-seq at the 29th meeting of Hematological malignancy clinical study group!
Nov. 21, 2024
Mina Yoshida delivered a talk on hareCLIP-seq at the 29th meeting of Hematological malignancy clinical study group!
Nov. 9, 2024
Akihide Yoshimi has received the Excellence Award from the Japan Health Foundation!
Nov. 6, 2024
Tomoya Muto gave an invited lecture at the 97th Annual Meeting of the Japanese Biochemical Society!
Oct. 25, 2024
Our research proposal, Validation of the Target Suitability of Common Cancer Antigens for the Development of Cancer Prevention mRNA Vaccine has been selected for funding by AMED. PI: Akihide Yoshimi
Oct. 24, 2024
Kazuki Nishimura gave a talk on NECTIN4 at the 62nd Annual Meeting of Japan Society of Clinical Oncology!!
Oct. 21, 2024
Akihide Yoshimi gave a lecture at the LSBM Seminar at the University of Tokyo's Research Center for Advanced Science and Technology.
Oct. 15, 2024
Maiko Seki has joined as a master's student!
Oct. 13, 2024
Hirofumi Yamauchi gave an oral presentation on the B56a BRET sensor at the 86th Annual Meeting of the JSH!
Oct. 13, 2024
Mina Yoshida gave an oral presentation on hareCLIP-seq at the 86th Annual Meeting of the JSH!
more

Our Research Interest


Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.
wordle2.png
(Figure was made by using Wordle based on our recent papers)